Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Takeda will seek an external partner to leverage its cell therapy platform technologies
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Subscribe To Our Newsletter & Stay Updated
